vs
Side-by-side financial comparison of Plymouth Industrial REIT, Inc. (PLYM) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $51.2M, roughly 1.8× Plymouth Industrial REIT, Inc.). Vericel Corp runs the higher net margin — 25.0% vs -106.3%, a 131.3% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -1.4%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 0.4%).
Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
PLYM vs VCEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $51.2M | $92.9M |
| Net Profit | $-54.4M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | -102.5% | 24.1% |
| Net Margin | -106.3% | 25.0% |
| Revenue YoY | -1.4% | 23.3% |
| Net Profit YoY | -248.5% | 17.3% |
| EPS (diluted) | $-1.23 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $92.9M | ||
| Q3 25 | $51.2M | $67.5M | ||
| Q2 25 | $47.2M | $63.2M | ||
| Q1 25 | $45.6M | $52.6M | ||
| Q4 24 | $47.6M | $75.4M | ||
| Q3 24 | $51.9M | $57.9M | ||
| Q2 24 | $48.7M | $52.7M | ||
| Q1 24 | $50.2M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $-54.4M | $5.1M | ||
| Q2 25 | $-6.1M | $-553.0K | ||
| Q1 25 | $5.8M | $-11.2M | ||
| Q4 24 | $147.4M | $19.8M | ||
| Q3 24 | $-15.6M | $-901.0K | ||
| Q2 24 | $1.3M | $-4.7M | ||
| Q1 24 | $6.2M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | -102.5% | 5.1% | ||
| Q2 25 | -10.3% | -3.2% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | -29.6% | -4.3% | ||
| Q2 24 | 2.7% | -11.5% | ||
| Q1 24 | — | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | -106.3% | 7.5% | ||
| Q2 25 | -12.9% | -0.9% | ||
| Q1 25 | 12.8% | -21.4% | ||
| Q4 24 | 309.9% | 26.3% | ||
| Q3 24 | -30.1% | -1.6% | ||
| Q2 24 | 2.7% | -8.9% | ||
| Q1 24 | 12.4% | -7.5% |
| Q4 25 | — | $0.46 | ||
| Q3 25 | $-1.23 | $0.10 | ||
| Q2 25 | $-0.14 | $-0.01 | ||
| Q1 25 | $0.13 | $-0.23 | ||
| Q4 24 | $3.24 | $0.40 | ||
| Q3 24 | $-0.35 | $-0.02 | ||
| Q2 24 | $0.03 | $-0.10 | ||
| Q1 24 | $0.14 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $470.1M | $354.6M |
| Total Assets | $1.6B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $646.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $354.6M | ||
| Q3 25 | $470.1M | $321.9M | ||
| Q2 25 | $539.6M | $306.8M | ||
| Q1 25 | $571.0M | $295.5M | ||
| Q4 24 | $579.5M | $292.0M | ||
| Q3 24 | $436.5M | $257.5M | ||
| Q2 24 | $475.2M | $243.0M | ||
| Q1 24 | $484.6M | $233.9M |
| Q4 25 | — | $488.0M | ||
| Q3 25 | $1.6B | $453.3M | ||
| Q2 25 | $1.6B | $435.6M | ||
| Q1 25 | $1.4B | $424.6M | ||
| Q4 24 | $1.4B | $432.7M | ||
| Q3 24 | $1.5B | $390.4M | ||
| Q2 24 | $1.4B | $376.8M | ||
| Q1 24 | $1.4B | $356.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.12× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0M | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.0M | ||
| Q3 25 | $20.0M | $22.1M | ||
| Q2 25 | $23.4M | $8.2M | ||
| Q1 25 | $15.6M | $6.6M | ||
| Q4 24 | $96.1M | $22.2M | ||
| Q3 24 | $17.6M | $10.2M | ||
| Q2 24 | $19.9M | $18.5M | ||
| Q1 24 | $16.6M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.67× | — | ||
| Q4 24 | 0.65× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | 15.12× | — | ||
| Q1 24 | 2.67× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLYM
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
